The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I Study of Gemcitabine Combined with Radiotherapy with or Without Amifostine in Patients with Locally Advanced Head and Neck Cancer.
 
Kiyo Tanaka
No Relationships to Disclose
 
Gakuto Ogawa
No Relationships to Disclose
 
Junki Mizusawa
No Relationships to Disclose
 
Junko Eba
No Relationships to Disclose
 
Hiroshi Katayama
Honoraria - Ethicon
 
Kenichi Nakamura
Honoraria - Eisai; Merck Serono; Nihonkayaku; Taiho Pharmaceutical
 
Yasuhiro Shimada
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Tetsuya Hamaguchi
Honoraria - Chugai Pharma; Merck Serono; Novartis; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - NanoCarrier
Research Funding - Dainippon Sumitomo Pharma (Inst); MSD (Inst); NanoCarrier (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Yoshihiro Moriya
No Relationships to Disclose
 
Shin Fujita
No Relationships to Disclose
 
Seigo Kitano
Honoraria - Covidien; Ethicon; Olympus
 
Masafumi Inomata
Honoraria - Covidien; Ethicon; Olympus
 
Yukihide Kanemitsu
Honoraria - Chugai Pharma; Covidien; Daiichi Sankyo; Intuitive Surgical; Johnson & Johnson; MC Medical; Merck Serono; Seikagaku; Taiho Pharmaceutical; Takeda
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; Taiho Pharmaceutical